Aussie CSL Try To Acquire Talecris Of U.S. In Hands Of High-Profile Judge
This article was originally published in PharmAsia News
Executive SummaryThe attempt of Australia's CSL to acquire Talecris Biotherapeutics of the United States apparently is going to be decided by a U.S. judge familiar with politically charged trials. The U.S. Federal Trade Commission has objected to allowing the merger because of antitrust issues, and has laid out its complaints in details that have not been disclosed. CSL and Talecris expect to move to keep the complaint sealed and hearing the case would be Judge Colleen Kollar-Kotelly, the same judge who presided over the Microsoft antitrust case and who has handled several U.S. terrorism cases. CSL is concerned that unsealing the FTC complaint would reveal sensitive information about the blood-plasma industry and CSL itself. (Click here for more
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.